Genmab — Februar 2019
-
@Vester , this is what Jan said last Feb Q&A: Q: In january you started a “Study to evaluate Subcutaneous Daratumumab in
combination with Standard Multiple Myeloma Treatment Regimens”, which is a Phase
2. You already have the Phase 3 SC vs IV study; could these 2 clinical trials be the
basis for an overall approval of SC in all lines and settings?
Jan Van de Winkel: This is a good thought. -
Hans-Henrik om Genmab: http://www.proinvestor.com/debat/76737
-
12-13 minutter inde i udsendelsen.
-
Hans-Henrik overholder sin strategi. Det er fair nok. PS: Kan afsløre at han hungrer efter købssignalet efter brud
af 1.200. -
-
Den norske oliefond har øget ca 0,5% procent i Genmab i 2018 (hvis jeg husker ret) ? https://www.nbim.no/en/the-fund/holdings/holdings-as-at-31.12.2018/?fullsize=true
-
Tusinde tak Polle. Jeg sætter plusset i gang.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind